BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36913644)

  • 21. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.
    Jang SI; Lee HK; Chang EJ; Kim S; Kim SY; Hong IY; Kim JK; Lee HS; Yang J; Cho JH; Lee DK
    Cancer Immunol Immunother; 2023 Aug; 72(8):2757-2768. PubMed ID: 37165046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma.
    Odaka H; Hiemori K; Shimoda A; Akiyoshi K; Tateno H
    BMC Gastroenterol; 2022 Mar; 22(1):153. PubMed ID: 35350978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
    Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
    Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
    Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
    Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer.
    Kim Y; Yeo I; Huh I; Kim J; Han D; Jang JY; Kim Y
    Clin Cancer Res; 2021 Apr; 27(8):2236-2245. PubMed ID: 33504556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
    Bardol T; Dujon AM; Taly V; Dunyach-Remy C; Lavigne JP; Costa-Silva B; Kurma K; Eslami-S Z; Cayrefourcq L; Canivet C; Muscari F; Bournet B; Alix-Panabières C
    BMC Cancer; 2024 Jun; 24(1):709. PubMed ID: 38853244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study.
    Zhao R; Ren S; Li C; Guo K; Lu Z; Tian L; He J; Zhang K; Cao Y; Liu S; Li D; Wang Z
    Cancer Med; 2023 Feb; 12(4):5158-5171. PubMed ID: 36161527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
    Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
    Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
    Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.
    Radon TP; Massat NJ; Jones R; Alrawashdeh W; Dumartin L; Ennis D; Duffy SW; Kocher HM; Pereira SP; Guarner posthumous L; Murta-Nascimento C; Real FX; Malats N; Neoptolemos J; Costello E; Greenhalf W; Lemoine NR; Crnogorac-Jurcevic T
    Clin Cancer Res; 2015 Aug; 21(15):3512-21. PubMed ID: 26240291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
    Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
    Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
    Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
    Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
    Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
    Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes.
    Balasenthil S; Liu S; Dai J; Bamlet WR; Petersen G; Chari ST; Maitra A; Chen N; Sen S; McNeill Killary A
    Clin Chim Acta; 2023 Nov; 551():117567. PubMed ID: 37774897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
    Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
    Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu X; Bhandari K; Xu C; Morris K; Ding WQ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.